Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 777

1.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.

HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

2.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
3.

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.

AIDS. 2008 Jul 31;22(12):1389-97. doi: 10.1097/QAD.0b013e32830285fb.

PMID:
18614861
4.

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

Bánhegyi D, Katlama C, da Cunha CA, Schneider S, Rachlis A, Workman C, De Meyer S, Vandevoorde A, Van De Casteele T, Tomaka F.

Curr HIV Res. 2012 Mar;10(2):171-81.

PMID:
22339125
5.

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.

Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T, Lavreys L.

Int J STD AIDS. 2013 Jan;24(1):12-7. doi: 10.1258/ijsa.2012.012120. Epub 2013 May 6.

PMID:
23440570
6.

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman C, Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F.

AIDS. 2011 Apr 24;25(7):929-39. doi: 10.1097/QAD.0b013e328345ee95.

PMID:
21346512
7.

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.

Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719.

PMID:
21311113
8.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650
9.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
10.

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C.

HIV Med. 2012 Aug;13(7):398-405. doi: 10.1111/j.1468-1293.2012.00989.x. Epub 2012 Mar 14.

11.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
12.

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.

HIV Med. 2013 Aug;14(7):437-44. doi: 10.1111/hiv.12024. Epub 2013 Mar 10.

13.

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Béthune MP, Picchio G.

Antivir Ther. 2010;15(8):1161-9. doi: 10.3851/IMP1697.

PMID:
21149923
14.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
15.

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.

HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.

PMID:
22180523
16.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
17.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.

AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.

PMID:
20010070
18.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
19.

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team.

PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.

20.

[Darunavir as first-line therapy. The TITAN study].

Curran A, Ribera Pascuet E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:14-22. Spanish.

PMID:
19195455
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk